VYNE Therapeutics Inc (VYNE)
2.55
0.00 (0.00%)
USD |
NASDAQ |
May 31, 16:00
2.63
+0.08
(+3.14%)
After-Hours: 20:00
VYNE Therapeutics Research and Development Expense (Annual): 16.31M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 16.31M |
| December 31, 2022 | 18.38M |
| December 31, 2021 | 19.54M |
| December 31, 2020 | 43.53M |
| December 31, 2019 | 53.76M |
| Date | Value |
|---|---|
| December 31, 2018 | 52.99M |
| December 31, 2017 | 29.01M |
| December 31, 2016 | 11.26M |
| December 31, 2015 | 2.921M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
16.31M
Minimum
2023
53.76M
Maximum
2019
30.31M
Average
19.54M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Viking Therapeutics Inc | 63.81M |
| AN2 Therapeutics Inc | 54.87M |
| NovaBay Pharmaceuticals Inc | 0.068M |
| Palatin Technologies Inc | 22.63M |
| iBio Inc | 10.33M |